Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$35.35
-1.6%
$32.56
$27.34
$60.87
$6.55B0.191.37 million shs604,100 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$15.08
+1.3%
$14.72
$12.26
$16.89
$12.59B0.331.52 million shs583,438 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.05
$16.99
$12.47
$22.80
$19.51B0.610.28 million shs5.55 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$294.57
-0.2%
$301.21
$266.98
$417.82
$13.28B0.53445,641 shs284,212 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.00%+2.08%+12.29%+10.43%-23.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.00%+0.13%-2.80%+21.93%-0.85%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.00%+1.76%-1.07%+23.28%+1.49%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+3.62%-7.86%+0.72%-5.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
3.1104 of 5 stars
4.51.00.00.02.61.70.6
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.7025 of 5 stars
2.54.01.70.01.50.01.9
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
4.1448 of 5 stars
4.63.00.00.02.41.71.9
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
4.9954 of 5 stars
4.35.00.04.62.93.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$72.60105.37% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.00
Buy$16.9512.40% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.22
Buy$24.1341.50% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$386.1531.09% Upside

Current Analyst Ratings Breakdown

Latest TEVA, UTHR, LEGN, and RDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00 ➝ $54.00
6/30/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$410.00 ➝ $385.00
6/26/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $23.00
6/11/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.00
6/6/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00
6/5/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/5/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$14.44 ➝ $16.90
6/2/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$405.00
5/28/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
5/27/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $71.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M10.36N/AN/A$5.70 per share6.20
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B3.30$1.03 per share14.60$4.73 per share3.19
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.18$3.37 per share5.06$4.74 per share3.60
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$2.88B4.62$28.41 per share10.37$144.34 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.6622.8518.395.3317.38%17.98%12.24%7/25/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.480.87-7.74%45.44%6.95%7/30/2025 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.20B$25.0611.7510.726.4540.44%19.33%16.73%7/30/2025 (Estimated)

Latest TEVA, UTHR, LEGN, and RDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64N/AN/AN/A$4.34 billionN/A
7/30/2025Q2 2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.89N/AN/AN/A$802.13 millionN/A
7/25/2025Q1 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.19N/AN/AN/A$88.27 billionN/A
5/13/2025Q1 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/9/2025Q4 24/25
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million
5/7/2025Q1 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
4/30/2025Q1 2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.29$6.63+$0.34$6.63$726.82 million$794.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.080.53%N/A12.12%N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
5.20
5.07
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.02
1.92
1.37
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.59
1.03
0.74
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.46
5.23

Institutional Ownership

CompanyInstitutional Ownership
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.89 million818.19 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,30545.11 million40.46 millionOptionable

Recent News About These Companies

United Therapeutics Corporation (UTHR) - Yahoo Finance
UTHR United Therapeutics Corporation - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$35.35 -0.56 (-1.56%)
Closing price 07/3/2025 02:47 PM Eastern
Extended Trading
$35.35 0.00 (0.00%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$15.08 +0.20 (+1.34%)
As of 07/3/2025 03:30 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$17.05 0.00 (0.00%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$17.05 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$294.57 -0.65 (-0.22%)
Closing price 07/3/2025 02:47 PM Eastern
Extended Trading
$294.57 0.00 (0.00%)
As of 07/3/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.